FiercePharma10d
Regeneron's Libtayo reaches blockbuster status and has potential for more growth: execs
Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...
Citius Pharmaceuticals and Citius Oncology announce J-Code issued for Lymphir
Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR) announced that Lymphir has been assigned a unique, ...
PharmiWeb5d
Libtayo® (cemiplimab) Now Available on the National Health Service in Scotland for Patients with Recurrent or Metastatic Cervical Cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab ... management of patients with cervical cancer - Update 2023. Int J Gynecol Cancer ...
Yahoo Finance9d
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
Effective April 1, 2025, healthcare providers may use the permanent J-code, J9161 (Injection, denileukin diftitox-cxdl, for intravenous use, 1 microgram), when submitting claims for LYMPHIR.
Investing9d
Citius Pharma's LYMPHIR gains permanent J-code for billing
The J-code, J9161, will be effective starting April 1, 2025, and will facilitate the billing process for healthcare providers administering LYMPHIR for the treatment of adult patients with Stage I ...
Investing9d
Citius Pharma's LYMPHIR gains permanent J-code for billing
J-code for their drug LYMPHIR by the Centers for Medicare & Medicaid Services (CMS). The J-code, J9161, will be effective starting April 1, 2025, and will facilitate the billing process for healthcare ...